Daily Brief Health Care: Insilico Medicine, Eloxx Pharmaceuticals , GenScript Biotech and more

• Insilico Medicine (3696 HK) has risen since its 1H26 earnings announcement.  The company’s rentosertib drug reversed biological aging markers in its Phase IIa trial.
• Rentosertib holds a singular distinction: it is the first end-to-end AI-discovered and AI-targeted drug to reach Phase III clinical development globally.
• The China CDE permitted a direct jump from Phase IIa to Phase III based on efficacy data, an unusual regulatory concession.

• Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel, small molecule product candidates to modulate the ribosome and promote readthrough of premature stop codons.
• Exaluren received Orphan Drug Designation from the FDA for AS, with Phase 2b topline data anticipated by mid-2027.
• The company reported net losses of $8.3 million for the six months ended June 30, 2026, with an accumulated deficit of $308.8 million.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• GenScript Biotech (1548 HK) is placing 77M shares at the price of HK$30.50 per placing share. Placing shares represent approximately 3.5% of the total number of issued shares.
• The company intends to use the proceeds mainly for expansion of capacity and infrastructure of AI-driven drug discovery platform, including automated high-throughput wet-lab facilities, related equipment, and laboratory upgrades.
• GenScript is witnessing accelerating demand for AIDD. During 1H26, AIDD business doubled and maintained rapid growth for a third consecutive half-year reporting period.